MedPath

Autologous Stem Cell Transplantation in Patients with Systemic Sclerosis

Phase 2
Recruiting
Conditions
Diffuse Sclerosis Systemic
Interstitial Lung Disease
Pulmonary Hypertension
Systemic Sclerosis
Interventions
Registration Number
NCT03630211
Lead Sponsor
Paul Szabolcs
Brief Summary

The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment effect.

Detailed Description

This is a single center, phase II trial where after a process of stem cell mobilization and conditioning, subjects receive a CD34-selected autologous peripheral blood stem cell rescue. By virtue of positive selection for the stem/progenitor cell marker of CD34, the graft will be depleted for T, B and NK lymphocytes and other immune cells such as monocytes that may be pathogenic. This is an open label study and there will be no randomization or blinding as a part of this study.

The proposed regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment effect.

The primary objectives of this study are to determine the safety and treatment effect of high-dose immunoablative therapy followed by transplantation of CD34+ positively selected peripheral blood stem cells (PBSC) for systemic scleroderma (SSc) patients using a regimen designed to maximize patient safety while also aiming to eradicate autoreactive clones responsible for the disease. Safety will be determined by monitoring for death of any cause, and severe or life-threatening infections. Treatment effect will be determined by assessing event-free survival in comparison to a SSc observational cohort control group treated with standard of care medication (mycophenolate mofetil) at 12 and 36 months post hematopoietic stem cell transplant (HSCT). Enrolled subjects will be followed for survival, secondary malignancies, and SSC activity at least yearly up to 36 months post-HSCT.

The secondary objectives of this study are to:

* To assess cutaneous disease response to high dose immunosuppressive therapy (HDIT) by comparing pre- and post-transplant measurements of the modified Rodnan skin score (mRSS).

* To assess pulmonary disease response by longitudinally tracking FVC (pulmonary function test) and DLCO (diffusing capacity of the lung for carbon monoxide) yearly up to 36 months post-HSCT.

* To evaluate the treatment effect on disease activity/progression, as indicated by severity measures of cardiac, pulmonary, musculoskeletal, gastrointestinal, vascular and renal organ involvement, and need for concomitant disease-modifying antirheumatic drugs (DMARD) use.

* To evaluate quality of life by comparing pre- and post-transplant quality of life measurements. These measurements will include the Scleroderma Health Assessment Questionnaire (SHAQ), the Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36) and the Scleroderma Skin Patient Reported Outcome (SSPRO) pre- and post-mobilization.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
8
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Autologous Stem Cell TransplantationTotal Body IrradiationCD34-selected autologous stem cell being performed on CliniMACS depletion device. Conditioning regimen will not start sooner than 3 weeks, and ideally no more than 90 days, after cyclophosphamide dose in the mobilization regimen.
Autologous Stem Cell TransplantationAnti Thymocyte GlobulinCD34-selected autologous stem cell being performed on CliniMACS depletion device. Conditioning regimen will not start sooner than 3 weeks, and ideally no more than 90 days, after cyclophosphamide dose in the mobilization regimen.
Autologous Stem Cell TransplantationIntravenous immunoglobulinCD34-selected autologous stem cell being performed on CliniMACS depletion device. Conditioning regimen will not start sooner than 3 weeks, and ideally no more than 90 days, after cyclophosphamide dose in the mobilization regimen.
Autologous Stem Cell TransplantationCyclophosphamideCD34-selected autologous stem cell being performed on CliniMACS depletion device. Conditioning regimen will not start sooner than 3 weeks, and ideally no more than 90 days, after cyclophosphamide dose in the mobilization regimen.
Autologous Stem Cell TransplantationMesnaCD34-selected autologous stem cell being performed on CliniMACS depletion device. Conditioning regimen will not start sooner than 3 weeks, and ideally no more than 90 days, after cyclophosphamide dose in the mobilization regimen.
Autologous Stem Cell TransplantationRituximabCD34-selected autologous stem cell being performed on CliniMACS depletion device. Conditioning regimen will not start sooner than 3 weeks, and ideally no more than 90 days, after cyclophosphamide dose in the mobilization regimen.
Autologous Stem Cell TransplantationAlemtuzumabCD34-selected autologous stem cell being performed on CliniMACS depletion device. Conditioning regimen will not start sooner than 3 weeks, and ideally no more than 90 days, after cyclophosphamide dose in the mobilization regimen.
Autologous Stem Cell TransplantationGM-CSFCD34-selected autologous stem cell being performed on CliniMACS depletion device. Conditioning regimen will not start sooner than 3 weeks, and ideally no more than 90 days, after cyclophosphamide dose in the mobilization regimen.
Autologous Stem Cell TransplantationThiotepaCD34-selected autologous stem cell being performed on CliniMACS depletion device. Conditioning regimen will not start sooner than 3 weeks, and ideally no more than 90 days, after cyclophosphamide dose in the mobilization regimen.
Primary Outcome Measures
NameTimeMethod
DeathPost Transplant through study completion, an average of 36 months

How many, if any, patients die

Respiratory FailurePost Transplant through study completion, an average of 36 months

defined by one of the following 3 criteria without explanation for causation other than disease progression: 1. decline in DLCO of ≥30% or FVC≥20% as measured by actual difference in percent predicted units; 2. Resting arterial p02 \< 60 mmHg or pCO2 \> 50 mmHg supplemental oxygen;3. Resting pulse oximetry of 88% or lower measured by forehead probe.

High Dose Immunoablative therapy-SafetyUp to 36 months post HSCT

Safety will be determined by monitoring for death of any cause, regimen-related toxicities, and severe or life-threatening infections.

Renal FailurePost Transplant through study completion, an average of 36 months

Defined by chronic dialysis for \>6 months or renal transplantation

Treatment-related mortality (TRM)Mobilization through study completion, an average of 36 months

defined as death occurring at any time after stem cell mobilization and definitely or probably resulting from treatment given in the study. TRM will be determined yearly with a focus on the first 2 years.

The occurrence of cardiomyopathyPost Transplant through study completion, an average of 36 months

confirmed by clinical congestive heart failure (New York Heart Association) or LVEF (left ventricular ejection fraction) \<30% on echocardiogram

High Dose Immunoablative therapy-Treatment Effectup to 36 months post HSCT (hematopoietic stem cell transplantation)

Treatment effect will be determined by assessing event-free survival in comparison to a SSc observational cohort control group treated with standard of care medication (mycophenolate mofetil) at 12 and 36 months post hematopoietic stem cell transplant (HSCT).

Secondary Outcome Measures
NameTimeMethod
An increase of mRSS (modified Rodnan skin score ) by ≥5 points for skin scoreDisease response will be defined as subject improvement. This will be assessed for both skin and interstitial lung disease at 12 and 24 months post-HSCT.

To assess cutaneous response the modified Rodnan skin score (mRSS) will be used.

Increase by ≥25% if the baseline mRSS > 20.Disease response will be defined as subject improvement. This will be assessed for both skin and interstitial lung disease at 12 and 24 months post-HSCT.

To assess cutaneous response the modified Rodnan skin score (mRSS) will be used.

Decrease in DLCO sustained for 3 months or longer on pulmonary function tests (PFT)1 year post transplant through study completion, an average of 36 months

to evaluate interstitial lung disease an increase of ≥15% in DLCO or ≥10% of FVC (actual change in % predicted units from baseline) sustained for ≥3 months on 2 determinations.

Development of scleroderma renal crisis (hypertensive or non-hypertensive)Post Transplant through study completion, an average of 36 months

Hypertensive renal crisis can be defined as a rise in SBP ≥ 30 points or DBP ≥ 20 points from baseline and one of the following: 1) Increase in baseline serum creatinine of ≥ 50%, 2) thrombocytopenia \< 100,000 plts/mm3 or 3. hemolysis by blood smear or increased reticulocyte count.

Worsening of > 10% of FVC (pulmonary function testing)1 year post transplant through study completion, an average of 36 months

to evaluate interstitial lung disease an increase of ≥15% in DLCO or ≥10% of FVC (actual change in % predicted units from baseline) sustained for ≥3 months on 2 determinations.

Worsening of cardiac involvementPost Transplant through study completion, an average of 36 months

With use of Imaging, EKG, Echocardiogram, Cardiac MRI, right heart cauterization, implanted loop recorder and 2 week cardiac event monitor. Defined as new or worsening arrhythmias that require medical treatment of 3 months or longer, or require ablative therapy, pacemaker or defibrillator insertion or defined as a decline in ejection fraction of ≥10 EF units, determined by echocardiogram.

Trial Locations

Locations (2)

Children's Hospital of Pittsburgh of UPMC

🇺🇸

Pittsburgh, Pennsylvania, United States

University of Pittsburgh Medical Center

🇺🇸

Pittsburgh, Pennsylvania, United States

Children's Hospital of Pittsburgh of UPMC
🇺🇸Pittsburgh, Pennsylvania, United States
Shawna McIntyre, RN
Contact
412-692-5552
mcintyresm@upmc.edu
Paul Szabolcs, MD
Contact
Robyn Domsic, MD, MPH
Contact
Annie Im, MD
Contact
Daniel Kass, MD
Contact
Geoffrey Kurland, MD
Contact
Robert Lafyatis, MD
Contact
Adam Olson, MD
Contact
Kathryn Torok, MD
Contact
Allison Morris, MD, MS
Contact
Kirsten Rose-Felker, MD
Contact
Franziska Rosser, MD, MPH
Contact
Paulina Horvei, MD
Contact
Joshua Levenson, MD
Contact
Archana Ramgopal, DO
Contact
© Copyright 2025. All Rights Reserved by MedPath